Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

s of $3.2 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements regarding the potential for commercializing tolevamer in the future, when data from this Phase 3 study of tolevamer will be presented and when the results of the second Phase 3 study of tolevamer will be available. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others, the actual safety and efficacy of tolevamer; the outcome of discussions with regulatory authorities regarding clinical studies and the approval of tolevamer for CDAD and the timing of such discussions; additional analysis of the data from the first Phase 3 study; the results of the second Phase 3 study and whether such results are consistent with this data; the timing of the second Phase 3 study; and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the qu
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
...  The Centers for Disease Control and Prevention (CDC) has ... as many people as car accidents.  Drug diversion is ... as the U.S. House of Representatives Energy and Commerce ... – "Prescription Drug Diversion: Combating the Scourge" ...
... SYDNEY, March 1, 2012  In a single bound, Nepean ... radiation therapy for its prostate cancer cases to a ... Arc Therapy), a technique that is even quicker with ... NCCC physicians treated their first patient with prostate cancer ...
Cached Medicine Technology:Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 2Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 3
(Date:4/22/2014)... is a popular high school sport in the United ... study by researchers in the Center for Injury Research ... to compare and describe the occurrence and distribution patterns ... high school athletic training setting among adolescents and teens. ... of Athletic Training , examined data relating to adolescents ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... of all lung cancers are small cell lung ... resistance to chemotherapy. However, researchers at Virginia Commonwealth ... into the mechanisms leading to this resistance that ... work primarily by mediating B-cell lymphoma 2 (Bcl-2) ... death. Depending on their function, this family of ...
(Date:4/22/2014)... The International Communication Association will hold its ... The theme of the 2014 conference will explore ... and digital society. , Featuring over 2,300 academic ... Communication scholars representing over 40 countries, the ICA ... in the world. This year,s conference features sessions ...
(Date:4/22/2014)... is available in German . ... intracellular signaling molecules, but their mode of action is ... cellular function and behavior, while at high concentrations they ... DNA. To analyze how redox signaling unfolds in single ... technique has been developed jointly by the teams of ...
Breaking Medicine News(10 mins):Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:Neuroimaging: Live from inside the cell 2
... effect on quality of life. New invasive procedures, such ... stimulation, may help patients with chronic refractory headache. This ... and co-authors from the Department of Neurology at the ... Deutsches rzteblatt International (Dtsch Arztebl Int 2011; ...
... Aug. 24 (HealthDay News) -- Exclusive breast-feeding of infants ... against developing the itchy skin disorder known as eczema ... an infant receives only breast milk, with no additional ... Exclusive breast-feeding up to 6 months of age is ...
... in the UK, US and Canada are undermining tobacco prevention ... report by public health researchers says. The paper, published in ... films with tobacco imagery should be ineligible for public funding ... public health goals. Earlier research shows that young people ...
... Reporter , TUESDAY, Aug. 23 (HealthDay News) -- From ... in what,s been dubbed the "mancession" are redefining their ... working partners, a small study suggests. University of ... interviews of 19 recently unemployed men. She and her ...
... HealthDay Reporter , TUESDAY, Aug. 23 (HealthDay News) ... to treat psoriasis -- an autoimmune disorder triggering itchy, ... linked to higher heart risks. But, the study ... makers impeded their ability to assess potential dangers noted ...
... , CHAMPAIGN, Ill. Assembling chemicals can be like ... developed a way of fitting the pieces together to ... and promising antioxidant. Led by chemistry professor Martin ... of the chemistry journal Angewandte Chemie . ...
Cached Medicine News:Health News:Breast-Feeding Won't Prevent Kids' Eczema, Researchers Say 2Health News:Government subsidies to the US film industry promote youth smoking, argue researchers 2Health News:In Tough Times, Jobless Men Embrace Housework 2Health News:In Tough Times, Jobless Men Embrace Housework 3Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:A new set of building blocks for simple synthesis of complex molecules 2
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
The link classic plus hip stem for cemented primary hip replacement surgery...
The uncemented hip joint prosthesis system...
The Quatroloc primary hip system offers 35 primary stems to fit almost all femurs for primary hip arthroplasty....
Medicine Products: